Highlights Journey Medical Corporation

Equities

DERM

US48115J1097

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
3.51 ^USD	-0.57%		-4.88%	-39.06%

May. 01	Journey Medical Corporation Appoints Joseph M. Benesch as Chief Financial Officer	CI
Mar. 21	Transcript : Journey Medical Corporation, 2023 Earnings Call, Mar 21, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Journey Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea	Mar. 18	CI
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 on Microbial Flora of Healthy Adults At 2024 Annual Meeting	Mar. 11	CI
Journey Medical Submits New Drug Application to FDA for Rosacea Treatment; Shares Rise	Jan. 05	MT
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea	Jan. 05	CI
Journey Medical Corporation Announces Successful Completion of Pre-Nda Meeting with the Fda for Dfd-29 to Treat Rosacea	Dec. 06	CI
Journey Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Earnings Flash (DERM) JOURNEY MEDICAL CORPORATION Reports Q3 Revenue $34.5M	Nov. 07	MT
Earnings Flash (DERM) JOURNEY MEDICAL CORPORATION Posts Q3 EPS $0.99	Nov. 07	MT
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29	23-10-20	CI
Journey Medical Grants Exclusive License to Maruho for Manufacturing, Commercialization of Qbrexza in Asia	23-09-06	MT
Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza in South Korea and Other Asian Nations	23-09-06	CI
Earnings Flash (DERM) JOURNEY MEDICAL CORPORATION Posts Q2 Revenue $17.2M	23-08-08	MT
Journey Medical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 Mg) on Microbial Flora of Healthy Adult Subjects	23-06-13	CI
Earnings Flash (DERM) JOURNEY MEDICAL CORPORATION Posts Q1 Revenue $12.2M, vs. Street Est of $16.2M	23-05-22	MT
Journey Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
JOURNEY MEDICAL CORP Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-03-31	AQ
Earnings Flash (DERM) JOURNEY MEDICAL CORPORATION Reports Q4 Revenue $16M, vs. Street Est of $16.6M	23-03-29	MT
Journey Medical Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Journey Medical Corporation

Equities

DERM

US48115J1097

Highlights

Filters